Kiromic BioPharma, Inc. (KRBP)

OTCMKTS: KRBP · Delayed Price · USD
0.00 (0.00%)
Nov 27, 2023, 2:04 PM EST - Market open

Company Description

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors.

The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.

It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L.

The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019.

Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Kiromic BioPharma, Inc.
Kiromic BioPharma logo
Country United States
Founded 2006
IPO Date Oct 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 31
CEO Pietro Bersani CPA, J.D.

Contact Details

7707 Fannin St., Suite 140
Houston, Texas 77054
United States
Phone 832-968-4888

Stock Details

Ticker Symbol KRBP
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
IPO Price $12.00
CIK Code 0001792581
CUSIP Number 497634105
ISIN Number US4976342042
Employer ID 46-4762913
SIC Code 2836

Key Executives

Name Position
Pietro Bersani CPA, J.D. Chief Executive Officer and Director
Dr. Scott Dahlbeck M.D., Pharm.D., PharmD Chief of Staff
Daniel Clark Chief Financial Officer
Dr. Leonardo Mirandola Ph.D. Chief Scientific Officer
Dr. Michael Ryan Ph.D. Chief Bioinformatics Research Computing Officer

Latest SEC Filings

Date Type Title
Nov 20, 2023 25-NSE Filing
Nov 14, 2023 10-Q Quarterly Report
Nov 9, 2023 8-K Current Report
Nov 6, 2023 8-K Current Report
Oct 3, 2023 8-K Current Report
Oct 2, 2023 8-K Current Report
Sep 26, 2023 8-K Current Report
Sep 13, 2023 8-K Current Report
Aug 29, 2023 8-K Current Report
Aug 15, 2023 S-8 Securities to be offered to employees in employee benefit plans